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Basket clinical trials are a new category of early clinical trials in which a treatment is evaluated in a
population of patients with tumors of various histologic types and primary sites selected for containing
speciﬁc genomic abnormalities. The objective of such studies is generally to discover histologic types in
which the treatment is active. Basket trials are early discovery trials whose results should be conﬁrmed
in expanded histology speciﬁc cohorts. In this report, we develop a design for planning, monitoring, and
analyzing basket trials. A website for using the new design is available at https://brbnci.shinyapps.io/
BasketTrials/ and the software is available at GitHub in the "Basket Trials" repository of account brbnci.
& 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
A major focus of oncology drug development involves use of
tumor genomics to guide the use of molecularly targeted drugs.
When the action of a drug is mediated by a de-regulated molecular
target whose role in the pathophysiology of the tumor is well
understood, then development of the drug and a companion
diagnostic in a histologic type of cancer is relatively straightfor-
ward [1]. However, activity of a drug against tumors of a histologic
type bearing a genomic alteration does not always imply that the
drug will be active against tumors of other histologic types bearing
the same alteration. Also, even for a single histologic type, there
may be multiple alterations in the same pathway (or gene) of
interest and performing a separate clinical trial for each alteration
may not be feasible. Because phase III clinical trials generally test a
single hypothesis about the effectiveness of a drug in a prespeci-
ﬁed population of patients, these uncertainties must generally be
resolved in earlier phase clinical trials. For this reason, a new type
of early phase clinical trial has arisen, the "basket trial" [2].
The basket trial represents an early phase II discovery trial in
which patients with deﬁned genomic alterations but multiple
histologic types of tumors are selected to discover in which
histologic types of tumors the targeted drug is active. If the
selection includes a variety of types of genomic alterations or a
variety of mutated genes, the basket trial may also be designed to
determine which alterations in which genes sensitize the tumor toInc. This is an open access article uthe drug. To perform a standard phase II trial in each histologic
type of tumor or for each genomic alteration is often not feasible.
Basket trials are discovery trials rather than hypothesis testing
trials; promising results of drug activity for a subset should be
conﬁrmed in an expanded phase II where possible. Although
basket trials are ongoing in many major cancer centers [3], new
statistical designs that address the special features of basket trials
have not been previously reported. Here we describe such a
design. We have also developed a website https://brbnci.shi
nyapps.io/BasketTrials/ so that others can consider using this
design for their studies.2. The model
2.1. Prior distribution
Assume that there is one treatment and K strata of patients. If
all of the patients have a common genomic alteration in their
tumors, then the strata will represent different histologic types of
patients. However, in some cases, eligibility may include tumors
with different alterations of the same gene or alterations in
different genes in the same signaling pathway. In those cases the
strata may represent subsets with different alterations or different
alterations and histologic types. Let pk denote the response
probability for stratum k. We are interested in determining
whether the treatment is active or not, ie, pk Z phi for each
stratum k. We take a Bayesian approach with a two point
parameter space for each stratum; that is pk is either phi or plo
as has been used previously in phase two clinical trials [4].nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
K patient strata
rk responses in nk patients for each stratum k
Compute  = posterior probability 
treatment effects are equal among 
strata
Compute P0=probability drug is active in all strata 
assuming strata are homogeneous
Compute for each k=1,2,...K
Pk,ind = probability drug is active in stratum k 
assuming strata are independent
Posterior probability  drug is active in stratum k equals
Pk =  P0 + (1- ) Pk,ind
Fig. 1. The basket consists of K disjoint patient strata. The strata usually represent
patients with K histologic types of cancer whose tumors contain a similar genomic
alteration. The model assumes that the response probabilities to the test drug
regimen are either the same for all strata or are not equal but can be viewed as
independent samples from the same distribution. The probability of response is
dichotomized into an active level and an inactive level. At each interim analysis the
probability of activity is computed for each stratum in a manner similar to that
shown in the ﬁgure.
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probabilities Pr[p ¼ x] where p denotes the vector (p1 ,…,pK) and
x denotes a vector of K components each of which is either plo or
phi. This represents the speciﬁcation of 2K quantities, which must
sum to 1. The approach we will describe, however, requires the
elicitation of only two parameters in additional to plo and phi. Our
model incorporates two hypotheses. One hypothesis is that the
response probabilities in the strata are identical, ie, the activity of
the drug does not depend on histologic type of the tumor. In this
case either the drug is active in all strata or in none. λ denotes the
prior probability that the strata are completely correlated. The
other hypothesis is that drug activity in different strata are
independent. γ denotes the prior probability that the drug is active
in any speciﬁc stratum.
2.2. Interim analysis
At any point in the trial, we can compute the posterior
probabilities Pr[p ¼ x]for all of the 2K x vectors. The posterior
probabilities depend on the numbers of responses and sample
sizes in each of the K strata at that time. Let those numbers be
denoted by the vectors r and n respectively. That is, for stratum k
there are rk responses in nk patients. The posterior probability can
be written:
Pr½p¼ xjr,n ¼ cPr½p¼ x ∏
K
k ¼ 1
xrkk ð1xkÞnkrk
where Pr[p ¼ x] is the prior probability that pk ¼ xk for k ¼ 1,…,
K and each element of the x vector is either plo or phi. The posterior
probability for a given x is the product of a normalizing constant
c times the prior probability, times the likelihood of the response
data observed up to that point if the response numbers are given
by the r vector and the sample sizes are given by the n vector. The
normalizing constant c can be determined to make the 2K
posterior probabilities sum to 1.
To compute the posterior probability of activity for a speciﬁc
stratum k Pr[pk ¼ phi|r,n], we sum all of the 2K-1 terms Pr[p ¼ x|
r,n] corresponding to xk ¼ phi.
We may compute these posterior probabilities for each stratum
at ﬁxed interim analysis times to determine which strata to close.
We would close a stratum if Pr[pk ¼ phi| r,n] is too small. If the
posterior probability of activity is very large for a speciﬁc stratum,
we might also close that stratum as the activity question has been
answered for that stratum. This early positive result can be used to
prompt initiation of a subsequent expanded phase II study of that
particular stratum. Particularly if accrual to that particular stratum
was fairly rapid, closing accrual to it after it exceeds a threshold for
the posterior probability of success can facilitate use of limited
resources which can be utilized for the treatment of patients in
less prevalent strata. The design is illustrated in Figs. 1 and 2.3. Results
Table 1 provides some examples of how the posterior proba-
bilities of activity depend on the response experience in all of the
strata. The examples are illustrated for a trial with three strata. The
prior probabilities were speciﬁed using the parameters Υ ¼ 0.33
and λ ¼ 0.5 indicating the prior probability that the drug is active
in any particular stratum is 0.33 and the probability that the
activities are perfectly correlated across strata is 0.5. We used
phi ¼ 0.25 and plo ¼ 0.05. The ﬁrst three columns of the table
show the response data at the time of the interim analysis. The
ﬁnal three columns show the posterior probabilites of activity for
the three strata. The strata are ordered by prevalence. For the ﬁrst
two rows of the table, the response rates observed for strata 1 and2 are equal to 0.30, ie, 6/20 and 3/10, respectively. The posterior
probabilities of drug activity for the ﬁrst two strata are large. The
strong inference in stratum 2 is based on borrowing information
from the activity seen in stratum 1, the prior probability of 0.5 that
the strata are perfectly correlated, and that 3/10 is more consistent
with a response rate of 25% than one of 5%. In the ﬁrst row the
response rate for stratum 3 is 1/5 and the posterior probability of
activity for stratum 3 is surprisingly large at 0.90. Clearly, infor-
mation is being borrowed from strata 1 and 2. In the second row
the response rate for stratum 3 is 0/5 and the posterior probability
of activity in stratum 3 drops substantially in spite of the activity
seen in strata 1 and 2. The next three rows of the table show cases
in which the response rate for the dominant stratum 1 is only 1/20
at the interim analysis but remains 3/10 for stratum 2. In this case,
the posterior probability of activity for stratum 2 is large, in spite
Input K = number of strata
=prior probability drug activity is homogeneous 
=prior probability of drug activity in a stratum
N=maximum sample size
phi=response probability for active drug
plo=response probability for inactive drug
n=accrual between interim analyses
T=threshold for conclusive posterior probability
Accrue n additional total 
patients to open strata
Update posterior probability Pk 
that drug is active in stratum k 
for each stratum
If Pk<1-T declare drug inactive in stratum k 
If Pk>T declare drug active in stratum k
In either case, terminate accrual to stratum k
If any strata are still open and 
total sample size is < N then
Fig. 2. Graphical representation of the speciﬁcation of initial parameters and the interim analyses.
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analysis is not locked in to assuming that activity is correlated
across the strata. Whether the posterior probability of activity for
stratum 2 is large enough to trigger shutdown of accrual to the
stratum depends on the threshold used. The BATTLE I clinical trial
promoted treatments if the posterior probability of activity
exceeded 0.80. The posterior probability of activity for the most
prevalent stratum 1 is low [5]. That probability of activity ranges
from 0.04 to 0.18 depending on the number of responses seen in
the less prevalent stratum 3. Accrual to stratum 1 might be
curtailed following this interim analysis depending on what
threshold for closing down a stratum is used.Table 1
Illustration of how strata-speciﬁc posterior probability of activity depends on
response rates in all strata.
Response rate at interim analysis Posterior probability of activity
Stratum 1 Stratum 2 Stratum 3 Stratum 1 Stratum 2 Stratum 3
6/20 3/10 1/5 0.99 0.98 0.90
6/20 3/10 0/5 0.99 0.96 0.58
1/20 3/10 0/5 0.04 0.80 0.13
1/20 3/10 1/5 0.11 0.86 0.50
1/20 3/10 2/5 0.18 0.91 0.864. Expected number of discoveries
Table 2 shows the results of computer simulations with three
strata as a function of the number of strata in which the drug was
active. In these simulations, interim analyses to update the
posterior probabilities of activity for each stratum are conducted
after every group of ﬁve evaluable total patients. We assumed that
the strata were equally prevalent and that accrual to a stratumwas
closed if the posterior probability of activity was either less than
0.2 or greater than 0.8. Otherwise, accrual continued for that
stratum. The trial was also terminated after 50 total patients if
previously all of the strata had not already been closed. Results
of 1,000 simulations with plo ¼ 0.05, phi ¼ 0.25, λ ¼ 0.33 and
γ ¼ 0.5 are shown in Table 2. With zero or three active strata
the homogeneity hypothesis is true and activity decisions are
achieved early. With one or two active strata, the homogeneity
hypothesis is false and there is less sharing of information among
strata.
Table 3 shows results as a function of the number of strata
using the same parameters as in Table 2 and thresholds less than
0.2 or greater than 0.8 for closing accrual to a stratum. Here we
computed the average error rates per positive and negative strata
when the activity status of the drug in each stratum is averaged
over the prior distribution. The average false positive rate is the
number of false positives divided by the expected number of strata
in which the drug was inactive; similarly for false negatives. There
Table 2
Bayesian basket design with three strata.
No. of active
strata
Expected no. of true
discoveries
Expected no. of false
discoveries
Average total
sample size
0 0 .12 23.8
1 .61 .14 27.3
2 1.42 .15 27.5
3 2.61 0 22.4
Interim analysis was performed after every ﬁve patients. A stratum was closed
when posterior probability of activity was o0.2 or 40.8.
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K ¼ 10 because the computations become more time consuming.
For K ¼ 3 or 5 we used nmax ¼ 50 but for K ¼ 10 we used nmax
¼ 70. The average total sample size till all strata were closed
increased from 25.4 for three strata, to 35.8 for ﬁve strata and 54.3
for 10 strata. An optimum two-stage design [6] for distinguishing a
response probability of 0.05 from 0.25 with type I and type II error
rates of 0.20 would have a ﬁrst stage of 6 patients and a total
sample size of 16 patients. Using this type of design separately for
each stratum could require substantially more patients than the
Bayesian designs used in Table 3 although their operating charac-
teristics are quite different. The simulation we performed can be
conducted in planning a basket trial using the relative prevalence
across the strata expected for the trial instead of assuming the
strata are equally prevalent as for the simulations reported here.
The website we provide permits unequal prevalence to be speci-
ﬁed. The parameters plo, phi, λ and γ and the frequency of interim
analyses can be tailored to the speciﬁc trial.Table 3
Bayesian basket design with interim analysis after every 5 patients.
No. of
strata K
True
positive
rate
False
negative
rate
False
positive
rate
True
negative
rate
Average total
sample size
3 .85 .15 .10 .90 25.4
5 .84 .16 .14 .86 35.8
10 .83 .17 .19 .81 54.3
A stratum was closed when posterior probability of activity was o0.2 or 40.8.5. Examples
Table 4 shows response rates for 10 strata of cancer types in a
basket trial of the BRAF inhibitor vemuraﬁnib reported by Hyman
et al [7]. For our model, we used the parameters plo ¼ .15, phi ¼
.35 indicated by the authors as of interest to them with λ ¼ 0.33
and γ ¼ 0.5. With these parameters we computed that the
posterior probability of homogeneity of treatment effects among
the strata was only 0.008. Because the posterior probability of
homogeneity is so small with these 10 strata, there is little
borrowing of information among strata. The posterior probabilities
of activity of the drug in each of the 10 strata are shown in the
table. The drug is very likely to be active for patients with BRAF
V600E mutations in NSCLC, Erdheim-Chester disease or Langer-
hans' cell histiocytosis, and PXA with posterior probabilities of
activity at the 35% level of 0.95, 0.90 and 0.82, respectively. The
drug is clearly not active in the colorectal cancer strata or in glioma
with posterior probabilities of activity of 0.03, 0.001, and 0.05.
Activity in cholangio cancinoma, anaplastic thyroid carcinoma,
multiple myeloma and the "other" category is less certain with
posterior probabilities of activity of 0.15, 0.41, 0.11 and 0.24,
respectively.
As a second example, we consider the design of a basket trial of
a PARP inhibitor for solid tumor malignancy patients with
relapsed/refractory advanced stage disease for whom no other
treatment options are available. Patients with genomic alterations
in one or more DNA repair genes are eligible and tumors are
categorized based on results from a DNA repair panel as complex
1 versus complex 2 vs. all other repair-related genes. An overall
response rate assessed at 8 weeks of at least 0.20 would be
considered promising for this advanced group of patients and no
activity was considered a response rate less than 0.05. The cancer
center considering this study expects to accrue approximately3 patients per month. It was considered desirable to limit the total
sample size to 50 patients.
An interim analysis was planned after evaluation of the ﬁrst 20
subjects. At interim analysis, the posterior probability of activity
for each stratum is computed using the pre-speciﬁed prior
probability parameters. Accrual to a stratum is terminated if the
posterior probability of activity becomes greater than 0.80 or less
than 0.20.
Sample size planning for this Bayesian basket trial was guided
through simulations using the interactive web based program.
Table 5 shows the expected values of the sample size, true positive
rate, false negative rate, false positive rate and true negative rate
where the number of active strata is averaged with regard to the
prior distribution. Since we could not determine in advance the
prevalence of each of the complex subgroup strata, we evaluated
this design in several different settings but held ﬁxed the values of
λ ¼ 0.50, γ ¼ 0.33. We constrained the maximum sample size to
50 evaluable patients.
Table 5 indicates that average power for identifying truly
positive effects for this drug seem adequate. The average proba-
bility of false positive rates fall somewhat above 0.20 when a
stratum has prevalence o0.30; however, these rates are still close
to 0.20 and our focus is to identify promising regimens to evaluate
further in an expanded cohort in subsequent studies. An optimal
two-stage design in each stratum would require 9–16 patients per
stratum or 27–48 patients total. When the strata are homogeneous
with regard to drug activity, the expected time to complete the
optimal two-stage designs will be longer. The comparison among
designs becomes more favorable to the Bayesian basket design as
the number of strata increases.
For this study, posterior probabilities of activity could be
computed as a function of histologic subset although the study
would not be powered for any formal evaluation within a histo-
logic type. Still, these would be used as valuable preliminary data
for hypothesis generation and planning future trials with this
regimen and/or this treatment approach. Posterior probability of
activity provides a convenient summary of data that reﬂects both
observed response rate and sample size. Even in the event of
insufﬁcient clinical activity, these ﬁndings along with correlative
measures of biomarker activity and targets would be useful in
designing future studies.6. Discussion
We have introduced a statistical model for planning, monitor-
ing and analyzing early phase basket discovery trials involving one
drug hypothesized to target tumors with speciﬁc genomic or
molecular characteristics. These types of discovery trials are useful
in the setting where eligibility is "histology agnostic" and focused
on those with the speciﬁc molecular target instead of the standard
paradigm of focusing on a given histology. In this setting, the
targeted patient population can consist of patients having multiple
histologic types and/or multiple genomic variants thought to make
Table 4
Posterior probabilities of activity (Z35%) for the Basket design of vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations [9].
NSCLC Colorectal
vemuraﬁnib
Colorectal vemuraﬁnib þ
cetuximab
Cholangio
carcinoma
ECD or
LCH
Anaplastic thyroid
carcinoma
Glioma MM PXA Other
Response rate 8/19 0/10 1/26 1/8 6/14 2/7 0/8 0/5 3/4 3/14
Posterior probability of
activity
.95 .03 .001 .15 .90 .41 .05 .11 .82 .24
NSCLC ¼ non-small cell lung cancer; ECD ¼ Erdheim-Chester disease; LCH ¼ Langerhans’ cell histiocytosis; MM ¼ multiple myeloma; PXA ¼ anaplastic pleomorphic
xanthoastrocytoma.
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importance in this era of 'omics' technologies and personalized
medicine [3] but when the number of patient strata increases, the
traditional phase II trial designs become less attractive. Especially
in the histology agnostic setting, it is not necessarily valid to
assume that the activity of the drug will be the same in all strata.
In the standard phase II trial setting, assessing different patient
groups requires separate adequately powered hypothesis testing in
each stratum based on the assumption that there is no relationship
among the strata; the corresponding sample size requirements can
be logistically challenging to achieve and the results may demon-
strate that the response rates for different strata were in fact
concordant.
The model we developed accommodates a-priori uncertainty
about how correlated the stratum-speciﬁc drug activities are and
borrows information across strata when the data indicates it is
warranted. The model is relatively easy to apply. The investigator
must prospectively specify the strata and the usual levels of
response probability corresponding to clinical or biologic activity
phi and inactivity plo. The investigator also speciﬁes two additional
parameters, the prior probability λ that the activity levels are
completely correlated across the strata, and the prior probability
γ that for any particular stratum the drug is active. A larger
γ results in a larger posterior probability of activity for the same
data although the effect of γ decreases with increasing sample size.
Studies of very promising treatments corresponding to a large
γ can sometimes provide large posterior probabilities of activity
with smaller sample sizes than would be required by frequentist
planning with the standard type I and type II error criteria. This
relates to the so called “type III error”, the error we make by failing
to discover an effective treatment because we do not perform the
relevant clinical trial.
The monitoring of the trial using the model introduced here
amounts to just computing the posterior probability of activity for
each stratum. Although Bayesian posterior probabilities do not
require pre-speciﬁcation of interim analysis times, for purposes of
data quality it is generally best to have pre-speciﬁed interim
analyses either based on calendar time or total number of patientsTable 5
Operating characteristics for planned three strata Basket design as function of the strat
Prevalence per stratum Expected
sample size
True positive
rate
False nega
rate
Complex 1 Complex 2 Others
0.33 0.33 0.33 34 0.84 0.16
0.40 0.40 0.20 35 0.86 0.14
0.50 0.30 0.20 34 0.87 0.13
0.40 0.30 0.30 35 0.85 0.15
0.50 0.30 0.20 34 0.86 0.14
0.50 0.40 0.10 34 0.87 0.13
0.50 0.35 0.15 34 0.85 0.15
0.45 0.45 0.10 34 0.86 0.14evaluable. At each interim analysis, the posterior probabilities are
computed and decisions are made about which strata to continue
and which not to continue. These decision rules need not be pre-
speciﬁed for the validity of Bayesian posterior probabilities, but it
will generally be useful to establish such rules prospectively so
that issues of trial management and interpretation can be consid-
ered from the outset. In this process, it will be useful to conduct
clinical trial simulations as described above and giving the
operating characteristics shown in Table 3. Such simulations can
be performed using the web-based interactive program at https://
brbnci.shinyapps.io/BasketTrials/. These operating characteristics
do require speciﬁcation of the interim analysis interval and the
decision rule for closing accrual to a stratum based on interim
results. Control of the average true and false discovery rates should
determine the maximum sample size, decision rules for declaring
activity or inactivity, and the monitoring plan. This design does not
provide strong control of the type I and type II error rates for each
stratum under all possible conﬁgurations of drug activity among
the strata [4]. If such control is deemed necessary, a standard
phase II design for each stratum separately should be used [6]. We
believe that such strong control is not necessary for many basket
discovery trials, however, and that the expected number of true
and false discoveries with regard to the prior distribution is an
appropriate criterion for a screening trial when separate phase II
studies are not feasible or where there is a substantial a-priori
probability that the strata are homogeneous with regard to drug
activity.
Previously developed statistical methods for phase II trials with
multiple strata could be used for the design and analysis of basket
trials. Leblanc et al [8] proposed a method which is similar to
conducting a traditional phase II trial within each stratum. It
differs however, in that a futility analysis of the pooled strata is
performed and stratum speciﬁc futility analyses are conducted
more frequently than with the optimal two-stage clinical trials [6].
Thall et al [9] developed a hierarchical Bayesian design for a
phase II design with strata consisting of subtypes of sarcoma.
Freidlin et al [4] evaluated these designs in simulations, however,
and found that the hierarchical prior resulted in minimal sharinga prevalences.
tive False positive
rate
True negative
rate
Probability of no false
positives when all strata are negative
0.17 0.83 0.81
0.22 0.78 0.79
0.22 0.78 0.81
0.20 0.80 0.77
0.23 0.77 0.80
0.25 0.75 0.81
0.23 0.77 0.81
0.24 0.76 0.82
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sharing, the amount determined by the parameter λ and by
the data.
The design we have introduced is ﬂexible, for example mod-
iﬁcations can be imposed where we set minimum sample sizes for
the strata to ensure sufﬁcient clinical experience before classifying
a given stratum as having insufﬁcient probability of drug activity.
The design does have limitations, however. It is limited to non-
randomized basket trials with a binary endpoint.
In non-randomized clinical trials it is difﬁcult to properly
interpret time to event outcomes because of the variable nature
of the pace of disease and the dependence on ascertainment. Some
phase II trials use disease control rates at a landmark time, eg,
8 weeks, as a binary endpoint. The Bayesian priors utilized here
could be generalized to priors on hazard ratios for use with
randomized basket trials. Such trials, however, would require
substantial increases in sample size to support within stratum
inference and this would not be consistent with the screening
objective.
The method described here requires the speciﬁcation of four
design parameters. Two of the parameters, plo and phi are
analogous to the parameters speciﬁed in standard phase II trial
designs. The parameter λ indicates the prior probability that the
true response probabilities are concordant among strata. A value
of 0.5 means there is no preliminary evidence favoring the
concordance of activity hypothesis over the independence
hypothesis. We recommend that the value of λ generally be set
somewhat less than 0.5, however, to avoid having excessive
sharing of information among strata early in the clinical trial
when sample sizes are small. In many cases the test drug will
have been previously active in another histologic type of tumor
and the basket trial will be screening for off-label use as in
Hyman et al [7]. In such cases, we recommend setting the value
of γ to 0.5.The approach described here can be generalized to settings
where we do not expect there to be complete symmetry among
the strata. For example, there may be four histology groups and
two types of genomic alterations for each histology groupeg, point
mutation or ampliﬁcation. There are eight strata and the γ values
may be different for the point mutation strata and the ampliﬁca-
tion strata. Also, the prior probability that the two mutation
groups within a histology group have the same activity level
may be greater than the prior probability that the histology groups
have the same activity level for a given mutation type. The given
model is easily modiﬁed to accommodate such modiﬁcations.Conﬂicts of interest
None.
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